Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET study

被引:102
|
作者
Pavese, Nicola [1 ]
Rivero-Bosch, Maria [1 ]
Lewis, Stephanie J. [1 ]
Whone, Alan L. [1 ]
Brooks, David J. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Ctr Neurosci, Dept Med, London SW7 2AZ, England
基金
英国医学研究理事会;
关键词
Positron emission tomography (PET); F-18-dopa; Noradrenaline; Serotonin; Parkinson; Monoamine; Extrastriatal; POSITRON-EMISSION-TOMOGRAPHY; DOPAMINERGIC FUNCTION; LOCUS-COERULEUS; FLUORODOPA; BRAIN; HYPOTHALAMUS; LEVODOPA; DOPA; ROPINIROLE; PATHOLOGY;
D O I
10.1016/j.neuroimage.2011.03.012
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Post-mortem and neuroimaging studies in Parkinson's disease (PD) have shown involvement of the brain serotoninergic, noradrenergic and cholinergic pathways alongside the characteristic degeneration of nigrostriatal dopamine neurons. The rate of progression of the degenerative process in these extrastriatal areas is still unclear. We used F-18-dopa PET, a marker of aromatic aminoacid decarboxylase activity in monoaminergic neurons, to assess longitudinal changes in tracer uptake in brain noradrenergic, serotoninergic and extrastriatal dopaminergic structures over a 3-year period in a group of early PD patients. Ten PD patients had F-18-dopa PET twice: at baseline and again after 37.1 +/- 21.5 months follow up. A standard object map was used to extract tracer influx constants (Ki) in 11 striatal and extrastriatal regions. Progressive decreases in F-18-dopa Ki occurred over the follow-up period in the majority of the investigated areas, the fastest annual declines occurring in putamen (8.1%), locus coeruleus (7.8%), and globus pallidus interna (7.7%). Caudate and hypothalamus showed 6.3% and 6.1% annual Ki declines, respectively. At baseline, some structures showed increased levels of F-18-dopa uptake in PD compared to controls (internal pallidum, locus coeruleus), indicating possible compensatory upregulation of monoamine turnover. These increased levels had normalised (globus pallidus interna) or become subnormal (locus coeruleus) at follow-up suggesting exhaustion of these mechanisms within the first years of disease. Loss of monoaminergic function in extrastriatal regions, as reflected by F-18-dopa PET, is delayed and occurs independently from nigrostriatal degeneration. When assessing the efficacy of novel neuroprotective agents on nigrostriatal dysfunction in PD. F-18-dopa PET could provide supplementary information concerning function of extrastriatal monoaminergic structures. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1463 / 1468
页数:6
相关论文
共 50 条
  • [21] An [F-18]dopa-PET and clinical study of the rate of progression in Parkinson's disease
    Morrish, PK
    Sawle, GV
    Brooks, DJ
    [J]. BRAIN, 1996, 119 : 585 - 591
  • [22] 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease
    Ceravolo, R
    Piccini, P
    Bailey, DL
    Jorga, KM
    Bryson, H
    Brooks, DJ
    [J]. SYNAPSE, 2002, 43 (03) : 201 - 207
  • [23] Striatal 18F-DOPA metabolism with PET-CT in patients with and without Parkinson's disease
    Schiepers, Christiaan
    Silverman, Daniel
    Dahlbom, Magnus
    Czernin, Johannes
    Phelps, Michael
    Huang, Sung-Cheng
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [24] 18F-DOPA PET and PET/CT
    Nanni, Cristina
    Fanti, Stefano
    Rubello, Domenico
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (10) : 1577 - 1579
  • [25] Comparison of 18F-DOPA and 18F-DTBZ for PET/CT Imaging of Idiopathic Parkinson Disease
    Shi, Xinchong
    Yang, Yang
    Jiang, Lulu
    Chen, Jinhua
    Yi, Chang
    Luo, Ganhua
    Wu, Lei
    Chu, Jianmin
    Wang, Jian
    Chen, Ling
    Zhang, Xiangsong
    [J]. CLINICAL NUCLEAR MEDICINE, 2022, 47 (11) : 931 - 935
  • [26] Orbitofrontal 18F-DOPA Uptake and Movement Preparation in Parkinson's Disease
    Marinelli, Lucio
    Piccardo, Arnoldo
    Mori, Laura
    Morbelli, Silvia
    Girtler, Nicola
    Castaldi, Antonio
    Picco, Agnese
    Trompetto, Carlo
    Ghilardi, Maria Felice
    Abbruzzese, Giovanni
    Nobili, Flavio
    [J]. PARKINSONS DISEASE, 2015, 2015
  • [27] Tremor at diagnosis is predictive of slower disease progression in Parkinson's disease:: An 18F DOPA PET study
    Whone, AL
    Brefel-Courbon, C
    Moore, RY
    Rascol, O
    Brooks, DJ
    [J]. MOVEMENT DISORDERS, 2002, 17 : S140 - S141
  • [28] STRIATAL DOPAMINERGIC DEGENERATION AND MOTOR AND COGNITIVE SYMPTOMS IN DE NOVO PARKINSON'S DISEASE: AN 18F-DOPA PET STUDY
    De Meyer, E.
    Meles, S.
    Van der Zee, S.
    Carli, G.
    Slomp, A.
    Slingerland, S.
    Goethals, I.
    Dierckx, R.
    Van Laar, T.
    [J]. PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [29] Progression of nigrostriatal dysfunction in Parkinson's disease: A longitudinal multimodal PET study
    Steidel, K.
    Ruppert, M.
    Greuel, A.
    Tahmasian, M.
    Maier, F.
    Hammes, J.
    van Eimeren, T.
    Timmermann, L.
    Tittgemeyer, M.
    Drzezga, A.
    Pedrosa, D.
    Eggers, C.
    [J]. MOVEMENT DISORDERS, 2021, 36 : S377 - S377
  • [30] Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study
    Y. F. Tai
    R. L. Ahsan
    J. G. de Yébenes
    N. Pavese
    D. J. Brooks
    P. Piccini
    [J]. Journal of Neural Transmission, 2007, 114 : 337 - 340